Workflow
Genetic Technologies(GENE)
icon
Search documents
Genetic Technologies Strategic Restructure Driving USA Sales Growth
Newsfilter· 2024-07-26 12:00
Transition to a capital light operating model; with lower cost operations Continued focus on the Company's core business of "EasyDNA" and "GeneType" Working capital funded by short term $800,000 secured loan (from lenders including Directors) Active Channel partners in the USA with geneType sales growth EasyDNA sales of $7m and growing The Company intends to fund working capital requirements with (i) a secured loan facility of $800,000; plus (ii) launching an Entitlement Offer. EasyDNA and AffinityDNA proje ...
Genetic Technologies Strategic Restructure Driving USA Sales Growth
GlobeNewswire News Room· 2024-07-26 12:00
Transition to a capital light operating model; with lower cost operations Continued focus on the Company's core business of "EasyDNA" and "GeneType" Working capital funded by short term $800,000 secured loan (from lenders including Directors) Active Channel partners in the USA with geneType sales growth EasyDNA sales of $7m and growing The Company intends to fund working capital requirements with (i) a secured loan facility of $800,000; plus (ii) launching an Entitlement Offer. EasyDNA and AffinityDNA proje ...
Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary
GlobeNewswire News Room· 2024-07-16 12:00
Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited. More recently, in roles as an executive, interim or non-executive director he has been supporting emerging, technology-driven businesses scale, g ...
Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary
Newsfilter· 2024-07-16 12:00
Forward Looking Statements MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and ...
GeneType to Enter Canadian and New Zealand Markets
Newsfilter· 2024-07-09 12:00
CHARLOTTE, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, today announced the introduction of geneType's suite of genetic risk assessment tests to Canada and New Zealand. Dovetailing geneType's recent expansion to the US market under its partnership with health and wellness technology leader Stayhealthy, Inc ("Stayhealthy"), t ...
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
GlobeNewswire News Room· 2024-06-25 12:00
GeneType is revolutionizing healthcare with its pioneering, non-invasive Multi-Risk Test, designed to uncover hidden risks of common yet serious diseases. This state-of-the-art test identifies individuals at elevated risk for a range of cancers, including breast, ovarian, pancreatic, prostate, colorectal, and melanoma, as well as cardiovascular diseases and metabolic conditions like Type 2 diabetes. Real Impact, Real Lives: About Genetic Technologies Limited Since the geneType Risk Assessment Tests became a ...
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
Newsfilter· 2024-06-25 12:00
CHARLOTTE, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide. Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling ...
Join Genetic Technologies' Exclusive Live Investor Webinar and Q&A Session on June 27
GlobeNewswire News Room· 2024-06-21 12:00
The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insight into the Company's portfolio of genomics-based tests targeting health, wellness and serious disease, including the geneType multi-risk test. Scaling existing sales channels - amplifying existing sales channels for enhanced market penetration and share. Aggressive marketing - harnessing our digital initiative to swiftly tap into the burgeoning direct-toconsumer market. Expanding t ...
Genetic Technologies Expands Operational Capacity in North America
Newsfilter· 2024-06-18 12:00
CHARLOTTE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, today announces the start of testing operations in the United States for its revolutionary geneType™ genetic risk assessment product series. Stemming from its significant contributions to the Human Genome Project nearly 20 years ago, GTG pioneered and patented the burgeoning area of genetic testing known ...
23andMe Launches New Genetic Report on Bipolar Disorder
GlobeNewswire News Room· 2024-06-05 11:00
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to ...